Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy
{{custom_author.name}}, {{article.zuoZheEn}}
Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy
[{{custom_ref.label}}] |
{{custom_citation.content}}
|
/
〈 | 〉 |